Kevin Curran

Dr. Kevin Curran is currently a biotech consultant in the field of gene therapy. Kevin provides market research and scientific insight on new genetic therapies in the disease categories of hemophilia, Duchenne muscular dystrophy and spinal muscular atrophy. These disease areas are currently being transformed by AAV viral vector gene therapies, anti-sense oligonucleotides and genome editing technology.

Kevin received his Bachelors of Science in Biology from Southern Oregon University and his PhD in Genetics from the University of Washington in Seattle. Prior to joining Biotech Primer, Dr. Curran worked in the field of cancer research at Memorial Sloan Kettering Cancer Center, where he analyzed the effect of small molecule therapies on cancer progression. Dr. Curran then worked in the stem cell field at UCSF and behavioral neuroscience at the Salk Institute.

For the past six years, Kevin has served as the biotech consultant at Biotech Primer. He delivers two day seminars on the science behind emerging medical therapies.